Sorry!! The article you are trying to read is not available now.
Thank you very much;
you're only a step away from
downloading your reports.

Why Single-Payer Health Care Can't Work


Some say this system would lead to rationing. They're right.

The visceral reaction to the Town Hall meetings on health-care reform leads me to believe that a lot of Americans feel that any single-payer system will inevitably lead to health-care rationing. And I couldn't agree more.

Way back in the early 1980s, I started out as a pharmaceutical/biotech analyst. Back then, I was frequently asked to talk at small meetings of clients at local offices of the regional brokerage firm that I worked for.

These clients were mostly small-business owners and a big issue was dealing with health-care expenses for their employees. I'd start out the talk with a quote from the retiring first Minister of the UK National Health System. (I've tried googling him and the exact quote, but it doesn't come up.) The quote is simple, direct, and as pertinent today as it was back in the 1950s and was very simple: "The demand for free health care is infinite." They all got it.

The people protesting now all get it. They all understand that free health care will lead to rationing. Rationing isn't starving to death, it's "You need a hip replacement -- no problem. But the waiting list is 3 years. In the mean time, limp." Check out the waiting lists in Canada and the UK, if you don't believe me. If you want understand real rationing, in the UK, kidney dialysis isn't offered to people above a certain age.

There are simply not enough doctors in the US to allow everyone to have a personal physician. In reality, we do have health care for everyone, but it's for acute health problems, not chronic problems. If you fall and break your wrist and you go to an emergency room, you get treated whether or not you have insurance. The chronic problems -- diabetes, high cholesterol, high blood pressure, and so forth -- occupy much of the time a family physician spends with patients. Most of these conditions have had significant advances in treatment through prescription drugs, so let's review some of the breakthroughs from the past 30 years.

The first breakthrough was Tagamet, the first antacid that actually reduced the production of stomach acid. Smith, Kline & French -- now GlaxoSmithKline (GSK) -- won FDA approval in 1979, and the number of people who had to have surgery for stomach ulcers rapidly declined. I believe stomach ulcer surgery was in the top-10 most frequently performed surgeries back the 1970s. You rarely ever hear of one now.

The next breakthrough was in high blood pressure. Two new classes of drugs emerged -- ACE inhibitors and calcium channel blockers. Controlling high blood pressure became much easier with minimal side effects.

The final major breakthrough was statins -- other than antibiotics, the greatest life-prolonging drug class ever developed. Study after study show huge reductions in heart attacks and strokes from the use of statins -- Pfizer's (PFE) Lipitor, Merck's (MRK) Zocor and many others.

So, where does that leave us in 2009? All the breakthrough ulcers drugs are over-the-counter. All previously doctor-prescribed, now they can be purchased at your local drug store. The over-the-counter versions were approved at one-half the dosage of the prescription version. Private insurance won't even pay for these ulcer drugs now.
< Previous
No positions in stocks mentioned.

The information on this website solely reflects the analysis of or o= pinion about the performance of securities and financial markets by the wri= ters whose articles appear on the site. The views expressed by the writers = are not necessarily the views of Minyanville Media, Inc. or members of its = management. Nothing contained on the website is intended to constitute a re= commendation or advice addressed to an individual investor or category of i= nvestors to purchase, sell or hold any security, or to take any action with= respect to the prospective movement of the securities markets or to solici= t the purchase or sale of any security. Any investment decisions must be ma= de by the reader either individually or in consultation with his or her inv= estment professional. Minyanville writers and staff may trade or hold posit= ions in securities that are discussed in articles appearing on the website.= Writers of articles are required to disclose whether they have a position = in any stock or fund discussed in an article, but are not permitted to disc= lose the size or direction of the position. Nothing on this website is inte= nded to solicit business of any kind for a writer's business or fund. M= inyanville management and staff as well as contributing writers will not re= spond to emails or other communications requesting investment advice.

Copyright 2011 Minyanville Media, Inc. All Rights Reserved.







Featured Videos